3
Announcements
Trials
Browse
Landscape
Status
Completed
77
Unknown
21
Terminated
10
Active not recruiting
4
Recruiting
3
Suspended
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
12
Pancreatic Neoplasms
7
Nasopharyngeal Carcinoma
5
Cholangiocarcinoma
5
Biliary Tract Neoplasms
4
Rectal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Colonic Neoplasms
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Stomach Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Urinary Bladder Neoplasms
1
Rare Tumour
1
Pathologic Complete Response
1
Pancreatic Cancer Resectable
1
PDAC - Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Second Primary
1
Neoplasms
1
Neoplasm, Residual
1
Neoadjuvant Chemotherapy
1
Muscle Neoplasms
1
Locally Advanced Low Rectal Adenocarcinoma
1
Liver Neoplasms
1
Liver Metastases of Colorectal Cancer
1
Keratosis, Actinic
1
HER2-positive Gastric Cancer
1
Gastroesophageal Junction Cancer
1
Interventions
Trastuzumab
16
pertuzumab
14
Capecitabine
14
Docetaxel
12
pyrotinib
11
Cyclophosphamide
11
Standard of Care
10
Paclitaxel
10
Letrozole
10
trastuzumab deruxtecan
9
Radiotherapy
9
Carboplatin
9
Fulvestrant
8
Drug Therapy
8
sacituzumab govitecan
7
dalpiciclib
7
exemestane
6
eribulin
6
Tamoxifen
6
Epirubicin
6
Anastrozole
6
pembrolizumab
5
palbociclib
5
abemaciclib
5
Surveys and Questionnaires
5
Neoadjuvant Therapy
5
Aromatase Inhibitors
5
camrelizumab
4
Sentinel Lymph Node Biopsy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Breast Neoplasms
×
Fluorouracil
×
Clear all
NCT06154590
2023-12-04
NASBP-B-09
Paradyne Networks A Foundation
Not yet recruiting
100 enrolled